Zobrazeno 1 - 10
of 601
pro vyhledávání: '"M. Villiger"'
Publikováno v:
Rheumato, Vol 4, Iss 2, Pp 63-74 (2024)
This work aimed to investigate a potential link between serum IL-1β levels in patients with giant cell arteritis (GCA) and their responsiveness to combined anti-IL-6 receptor (IL-6R) and glucocorticoid (GC) treatments within the context of two separ
Externí odkaz:
https://doaj.org/article/96feca8c25c444dab048f6503a88b95e
Autor:
Wolfgang A. Schmidt, Bhaskar Dasgupta, Jennifer Sloane, Angeliki Giannelou, Yuqing Xu, Sebastian H. Unizony, Sarah L. Mackie, Miguel A. Gonzalez-Gay, Robert Spiera, Kenneth J. Warrington, Peter M. Villiger, Michael C. Nivens, Bolanle Akinlade, Yong Lin, Frank Buttgereit, John H. Stone
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Background Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading to its approval. Thi
Externí odkaz:
https://doaj.org/article/4519641ec60d4627b6d5c6d36c1bb6ac
Autor:
Agnes Kocher, Michael Simon, Andrew A. Dwyer, Catherine Blatter, Jasmina Bogdanovic, Patrizia Künzler-Heule, Peter M. Villiger, Diana Dan, Oliver Distler, Ulrich A. Walker, Dunja Nicca
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-17 (2023)
Abstract Background The Chronic Care Model (CCM) is a longstanding and widely adopted model guiding chronic illness management. Little is known about how CCM elements are implemented in rare disease care or how patients’ care experiences relate to
Externí odkaz:
https://doaj.org/article/edcf93b955f742c8b50f474626664643
Autor:
Lisa Christ, Andrea D. Gloor, Florian Kollert, Timo Gaber, Frank Buttgereit, Stephan Reichenbach, Peter M. Villiger
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
ObjectiveProteome analyses in patients with newly diagnosed, untreated giant cell arteritis (GCA) have not been reported previously, nor are changes of protein expression upon treatment with glucocorticoids (GC) and/or tocilizumab (TCZ) known. The GU
Externí odkaz:
https://doaj.org/article/ab22f1dff0334cf28d896675155bdf8e
Autor:
Christophe Schmitt, Laura Brockwell, Mylène Giraudon, Mauro Zucchetto, Lisa Christ, Bettina Bannert, Thomas Daikeler, Peter M. Villiger
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background Subcutaneous tocilizumab (TCZ SC) is approved globally for giant cell arteritis (GCA). This phase Ib study investigated the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of intravenous (IV) TCZ 6 and 7 mg/kg
Externí odkaz:
https://doaj.org/article/58f15c8c5b414b1faed610a277a3f50c
Autor:
Mathis Komminoth, Marc Y Donath, Matthias Hepprich, Philipp Schuetz, Claudine A Blum, Beat Mueller, Jean-Luc Reny, Pauline Gosselin, Gautier Breville, Michael Brändle, Christoph Henzen, Jörg D Leuppi, Andreas D Kistler, Robert Thurnheer, Felix Beuschlein, Gottfried Rudofsky, Daniel Aeberli, Peter M Villiger, Stephan Böhm, Irina Chifu, Martin Fassnacht, Gesine Meyer, Jörg Bojunga, Marco Cattaneo, Constantin Sluka, Helga Schneider, Jonas Rutishauser, «TOASST» study group
Publikováno v:
PLoS ONE, Vol 18, Iss 4, p e0281585 (2023)
BackgroundDespite the widespread use of glucocorticoids in inflammatory and autoimmune disorders, there is uncertainty about the safe cessation of long-term systemic treatment, as data from prospective trials are largely missing. Due to potential dis
Externí odkaz:
https://doaj.org/article/d92743c036874326b2015c43279634bd
Autor:
Matthew A Brown, Peter M Villiger, Zhixiu Li, MUHAMMAD ASIM KHAN, Sjef M van der Linden, Heinz Baumberger, Hermine van Zandwijk, Mohammad Kazim Khan
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objective The lifetime recurrence rate (RR) of axial spondyloarthritis (axSpA) among first-degree relatives (FDR) and the effect of proband’s gender, HLA-B27 and radiographic status is unclear. Our 35-year-follow-up family study has enabled these i
Externí odkaz:
https://doaj.org/article/0693b53250bd4c8eaed38681adb0012f
Autor:
Agnes Kocher, Mwidimi Ndosi, Kris Denhaerynck, Michael Simon, Andrew A. Dwyer, Oliver Distler, Kirsten Hoeper, Patrizia Künzler-Heule, Anthony C. Redmond, Peter M. Villiger, Ulrich A. Walker, Dunja Nicca
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-9 (2021)
Abstract Background Rare disease patient-reported outcome measures (PROMs) require linguistic adaptation to overcome the challenge of geographically dispersed patient populations. Importantly, PROMs such as health-related quality of life (HRQoL) shou
Externí odkaz:
https://doaj.org/article/3e9d83106553412db3cb4a7816951e8a
Autor:
Jennifer Amsler, Iveta Kysela, Christoph Tappeiner, Luca Seitz, Lisa Christ, Godehard Scholz, Odile Stalder, Florian Kollert, Stephan Reichenbach, Peter M. Villiger
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-8 (2021)
Abstract Objectives Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) is able to prevent vision loss is unknown. The aim was to analyze the occurrence of vision loss in a large GCA cohort treated with TCZ. Methods I
Externí odkaz:
https://doaj.org/article/57fdeeb9b45243a494569927ada3fdc5
Autor:
Matthew A Brown, Peter M Villiger, Zhixiu Li, MUHAMMAD ASIM KHAN, Sjef M van der Linden, Heinz Baumberger, Hermine van Zandwijk, Mohammad Kazim Khan
Publikováno v:
RMD Open, Vol 8, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/8d5a7426b9f44322b96023c1e2ed5de2